M1 Kliniken AG Stock
Price
Target price
€17.76
€17.76
0.000%
-
0.000%
-
19.12.25 / Tradegate
WKN: A0STSQ / Name: M1 Kliniken / Stock / Healthcare Providers & Services / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
M1 Kliniken AG Stock
There is no change in the price for M1 Kliniken AG today.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for M1 Kliniken AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of M1 Kliniken AG in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Kliniken AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Kliniken AG | 0.000% | 2.069% | 11.839% | 11.698% | 6.667% | 131.854% | 103.204% |
| Mediclin AG | -1.110% | -3.226% | 2.273% | 52.542% | 51.261% | 6.509% | -5.263% |
| Vita 34 AG | -0.830% | -10.448% | 12.150% | 53.061% | 45.631% | -26.290% | -51.220% |
| Surgery Partners Inc | - | 1.515% | -0.741% | -29.101% | -32.323% | -43.460% | -42.735% |
News
EQS-News: Expansion of the Management Board of M1 Kliniken AG
EQS-News: Expansion of the Management Board of M1 Kliniken AG
EQS-News: M1 Kliniken AG reports strong EBIT Growth of 11% and achieves Earnings per Share of EUR 0.86.
EQS-News: M1 Kliniken AG reports strong EBIT Growth of 11% and achieves Earnings per Share of EUR 0.86.
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group